INTRODUCTION
The UK incidence of GTD is quoted as 1 in 714 live births, it has been noted to be higher amongst Asian females (1/387 live births) compared to non-Asian females (1/752 live births).
The Royal College of Obstetrics and Gynaecology green top guideline for Gestational Trophoblastic Disease suggest that all women should be provided with written information and referred for follow up by a trophoblastic screening centre.
METHODS
Retrospective data from women who were diagnosed with GTD at Wexham Park Hospital, over a period of five years from 2010-2014 was collected from CXH screening centre, WPH electronic databases: CRIS, PACs and ICE.
The accuracy of ultrasound diagnosis in detecting molar pregnancy and incidence, characteristics, symptoms of the local population was determined.
The management and registration of patients diagnosed with GTD was correlated according to RCOG guidance.
RESULTS
Fifty three patients were diagnosed with molar pregnancy over five years, 36% had a complete mole and 49% had a partial mole. Thirteen percent had persistent trophoblastic disease of which 3.7% were eventually diagnosed with non-persistent trophoblastic disease by CXH. One of the patients had three previous molar pregnancies.
The incidence of molar pregnancy over the five year period was 1 in 415.
The number of Asians diagnosed with GTD was 21% and Whites were 62%, 17% had ethnicity unspecified.
The patient age ranged from 16-55, majority were between the ages of 21-40, up to 40% were between 21-30 years and up to 50% were aged between 31 and 40 years. Only 6% were over 41 years and under 16 years old.
Over half of the women diagnosed were primiparous and 30% multiparous, about half had been diagnosed with subfertility and one third had a history of previous miscarriage ranging from one to five.
Most patients diagnosed were between seven and twelve weeks pregnant, the remaining 10% were five weeks and 13 -16 weeks of gestation or post early miscarriage.
More than half the diagnosis were from incidental finding, a third were diagnosed as a result of vaginal bleeding and less than 2% had persistently high BHCG.
Up to 50% had both (Trans-vaginal scan) TVS and (Trans-abdominal scan) TAS, up to 20% had a TVS only and 26% had a TAS only.
The use of ultrasound scan (USS) made the diagnosis of molar pregnancy likely in 40% of the patients; the suspicious features were missed miscarriage with cystic changes, irregular empty sac with snow storm appearance and an enlarged uterus with cystic changes in placenta or mixed echogenic areas and twin pregnancy with cystic changes.
Over half of the patients diagnosed with a molar pregnancy did not have any suspicious features on USS. Two thirds of the patients had a diagnosis of missed miscarriage; a few had a diagnosis of ectopic pregnancy, retained products of conception and a single viable intrauterine pregnancy.
The interval from USS findings to surgical management was within one week for majority of patients; less than 10% did not have the procedure till up to 4 weeks, 15% had the procedure within two weeks.
Only one fifth of suspected molar pregnancy was operated on by a consultant, the rest were evacuated by a registrar.
Most evacuations had no complications, less than 10% had an estimated blood loss (EBL) of 600 to 2000 ml.
All patients with a histological diagnosis of GTD were registered with CXH; most were registered within 1-4 weeks and at 5-7 weeks, 13% were registered between 8-16 weeks and less than 2% were registered after 18 months of histological diagnosis.
There was a delay of 2 months between sample collection and histology arriving in the laboratory for 5.7% of patients.
DISCUSSION

Main Findings
Our hospital had a higher rate of GTD 1/415 compared to the UK figure of 1/714, our incidence was higher in females of White ethnic background 60%.
There have been numerous studies looking at the epidemiology and aetiology of GTD, majority state a higher incidence amongst the Asian population, the trophoblastic screening centre at Weston Park Hospital, Sheffield specifically studied the Asian population and determined the incidence of 1 in 387 live births, even the Netherlands found an increasing incidence of GTD most likely due to an increase in Asian women giving birth. 5, 6, 7 There were no papers showing a higher incidence amongst the non-Asian population.
It has been shown that there is no relationship between treatment for infertility and development of GTD, 8 so we cannot suggest our high sub -fertility rate, of which
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We had a 3 in 1000 incidence of complete mole and nearly 5 in 1000 incidence of partial mole. Incidence of complete mole has been reported as 1 in 1000 and for partial mole 3 in 10009 again our numbers are comparable with national statistics.
Persistent trophoblastic disease was approximately 10% which is representative of the national average showing that although the incidence is higher, the sequel is similar amongst our patient group.
Only 6% of women were over the age of 41 years old, this does not fit in with the risks of maternal age as rates are supposed to be 7.5 times higher for women over the age of 40 years. 10 One third of women diagnosed with GTD had a history of miscarriage; As Parazzini et al 10 suggested this could be attributed to associated increase risk of molar pregnancy 2-3 fold if women had previous spontaneous miscarriage.
Majority of patients (83%) were diagnosed within the 1st trimester of pregnancy, but half of the patients were diagnosed as an incidental finding. This highlights the advancement of USS allowing GTD to be diagnosed before the onset of typical symptoms. 11, 12 USS detected 40% of molar pregnancy, as most of the diagnosis was before 14 weeks; this is representative of other studies that suggest a pre-evacuation diagnosis of molar pregnancy of 35-40% before 14 weeks. 13 Majority of patients had ERPC within one week from USS suggesting possible molar pregnancy. There are no guidelines for when ERPC for possible GTD should be carried out as most GTD are diagnosed after evacuation from histology. Offering ERPC within one week is good practice as earlier treatment results in decrease of complications.
14 Only 7.5% of patients had complications of bleeding more than 500 ml during ERPC which again is a comparable incidence.
Strengths and limitations
This was a five-year study allowing us to collect a good amount of cases increasing the accuracy of the results.
One limitation of our study was that we could attribute our increased rate of GTD to a low socioeconomic class and diet but in order to discuss this further we would need to collect more data.
CONCLUSIONS
At Wexham Park Hospital we have a higher than national average GTD rate 1 / 415 verses 1 / 714 and in females of non-Asian ethnic origin mainly White women.
In order to provide safe, quality care for patients diagnosed with GTD and improve early registration with the screening centre, we had implemented tissue nonviability forms which are completed promptly with the specimens from surgical management of miscarriages and ectopic pregnancies. This allows specimens to reach the lab on time avoiding processing delays and subsequent histological diagnosis.
Early registration of patients diagnosed with GTD allows prompt appropriate management by the screening centre. It has become the unit's policy that EPU consultants should be responsible for early pregnancy patients and review histology reports from surgical management of miscarriages and ectopic pregnancies to ensure prompt registration of relevant patients with the screening centre.
As a high proportion of histological diagnosis were from patients who had been diagnosed with missed/ delayed miscarriage on USS it is essential that patients who are being offered expectant management or medical management have follow up USS 3 weeks after expulsion of products of conception and a urine pregnancy test to exclude molar or persistent trophoblastic tissue.
